2024 ICD-10-CM Diagnosis Code T39.2X5D

Adverse effect of pyrazolone derivatives, subsequent encounter

ICD-10-CM Code:
T39.2X5D
ICD-10 Code for:
Adverse effect of pyrazolone derivatives, subs encntr
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics
        (T39)

T39.2X5D is a billable diagnosis code used to specify a medical diagnosis of adverse effect of pyrazolone derivatives, subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T39.2X5D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like adverse effect of pyrazolone derivatives. According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Adverse reaction to aldehyde
  • Adverse reaction to aminophenazone
  • Adverse reaction to chloral and/or chloral derivative
  • Adverse reaction to pyrazole derivative
  • Azapropazone adverse reaction
  • Dichloralphenazone adverse reaction
  • Dipyrone adverse reaction
  • Hypothyroidism caused by drug
  • Hypothyroidism resulting from phenylbutazone
  • Oxyphenbutazone adverse reaction
  • Phenylbutazone adverse reaction
  • Uricosuric agent adverse reaction

Clinical Classification

Clinical Information

  • Aminopyrine

    a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. a breath test with 13c-labeled aminopyrine has been used as a non-invasive measure of cytochrome p-450 metabolic activity in liver function tests.
  • Aminopyrine N-Demethylase

  • Antipyrine

    an analgesic and antipyretic that has been given by mouth and as ear drops. antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (from martindale, the extra pharmacopoeia, 30th ed, p29)
  • Dipyrone

    a drug that has analgesic, anti-inflammatory, and antipyretic properties. it is the sodium sulfonate of aminopyrine.
  • Feprazone

    a pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. it has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (from martindale, the extra pharmacopoeia, 30th ed, p15)
  • Oxyphenbutazone

    a non-steroidal anti-inflammatory drug. oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (from ama, drug evaluations annual, 1994, p2000) it had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (from martindale, the extra pharmacopoeia, 30th ed, p27)
  • Phenylbutazone

    a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. it has been used in ankylosing spondylitis; rheumatoid arthritis; and reactive arthritis.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T39.2X5D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T39.2X5D to ICD-9-CM

  • ICD-9-CM Code: V58.89 - Other specfied aftercare
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Table of Drugs and Chemicals

The parent code T39.2X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AmidopyrineT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
AminofenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
AminophenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
AminopyrineT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
AnalginT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
AntipyrineT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
AzapropazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
ButazolidinT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
ClofezoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
DiphenylbutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
DipyroneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
FenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
FenylbutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
FeprazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
HydroxyphenylbutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
IndocinT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
IsopropylaminophenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
KebuzoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
KetazonT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Metamizole sodiumT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
MethampyroneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
MofebutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
MonophenylbutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Myochrysin (e)T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
NifenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
NoramidopyrineT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Noramidopyrine
  »methanesulfonate sodium
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
OxyphenbutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
PhenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
PhenylT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Phenyl
  »butazone
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Phenyl
  »enediamine
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Phenyl
  »hydrazine
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Phenyl
  »hydrazine
    »antineoplastic
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Phenyl
  »mercuric compounds
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Phenyl
  »salicylate
T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
PhenylbutazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
PropyphenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
PyramidonT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Pyrazole (derivatives)T39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Pyrazolone analgesic NECT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
RamifenazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
SulfamazoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
SulfamidopyrineT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
SulpyrineT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
SuxibuzoneT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6
Tandearil, tanderilT39.2X1T39.2X2T39.2X3T39.2X4T39.2X5T39.2X6

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.